When rituximab, the monoclonal antibody, fails to induce responses for non-Hodgkin?s lymphoma (NHL) patients, the combination of tositumomab and iodine ¹³¹I (Bexxar) appears to produce durable complete responses. In a multi-center study of 40 patients with various types of NHL who failed to respond to or relapsed following rituximab treatment, 70% of the patients responded to Bexxar and 40% achieved a complete response, reports Sandra Horning of Stanford University, Stanford, CA., at the recent 42^nd Annual Meeting of the American Society of Hematology in San Francisco.
Go to Previous Page
Go to Next Page